Genetic is a molecular diagnostics company specialising in cancer genomics, and provides BREVAGenplus®, a clinically validated risk assessment test for non-hereditary breast cancer.
Under the new program, consumers will be able to initiate the testing by accessing the consumer initiated testing (CIT) platform via the company’s website www.brevagenplus.com.
Genetic’s recent shift to a patient self-pay program coupled with the on-going operational strategic review has served as catalysts to transform the commercial program into an ecommerce system.
CIT provides testing under the guidance and management of a remote physician using guideline driven protocols.
It ensures that a two-way patient physician relationship is established, results are interpreted correctly and abnormal results are flagged responsibly and communicated in a way to drive action.
A CIT platform, complemented by direct to consumer advertising, can reach two primary audiences through various channels and mediums.
First, the patient that qualifies for the product may be reached through multiple promotions and second, the healthcare provider that focuses on women’s health and breast health.
Under the refined commercial program, a BREVAGenplus dedicated staff member will be available telephonically to address product specification queries and provide more details about the test.